Advertisement

Status Epilepticus

  • Hannah BreitEmail author
  • Lauren Koffman
Chapter
  • 10 Downloads

Abstract

Status epilepticus is a neurologic emergency that requires prompt recognition and intervention, with the primary goal of controlling electrographic and clinical seizures, to avoid neuronal injury. This chapter aims to guide the clinician in defining status epilepticus, ordering appropriate diagnostic tests, and administering proper therapeutic interventions. It also provides insight into management of special patient populations and novel therapies on the horizon.

Keywords

Status epilepticus Refractory status epilepticus Seizures Epilepsy Neurocritical care Antiepileptic drugs Nonconvulsive status epilepticus Electroencephalogram 

References

  1. 1.
    Beran RG. An alternative perspective on the management of status epilepticus. Epilepsy Behav. 2008 Apr;12(3):349–53.PubMedCrossRefGoogle Scholar
  2. 2.
    Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5(3):246–56.PubMedCrossRefGoogle Scholar
  3. 3.
    Brophy G, Bell R, Claassen J, Alldredge B, Bleck T, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.PubMedCrossRefGoogle Scholar
  4. 4.
    Meldrum BS, Horton RW. Physiology of status epilepticus in primates. Arch Neurol. 1973;28(1):1–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Bleck TP. Refractory status epilepticus. Curr Opin Crit Care. 2005;11(2):117–20.PubMedCrossRefGoogle Scholar
  6. 6.
    Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(Pt 10):2802–18.PubMedCrossRefGoogle Scholar
  7. 7.
    Gaspard N, Foreman BP, Alvarez V, Cabrera Kang C, Probasco JC, Jongeling AC, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85(18):1604–13.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Goodkin HP, Yeh J, Kapur J. Status epilepticus increases the intracellular accumulation of GABAA receptors. J Neurosci. 2005;25(23):5511–20.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Goodkin HR, Joshi S, Kozhemyakin M, Kapur J. Impact of receptor changes on treatment of status epilepticus. Epilepsia. 2007;48(Suppl 8):14–5.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci. 2005;25(34):7724–33.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Shearer P, Riviello J. Generalized convulsive status epilepticus in adults and children: treatment guidelines and protocols. Emerg Med Clin North Am. 2011;29(1):51–64.PubMedCrossRefGoogle Scholar
  12. 12.
    Lv R, Wang Q, Cui T, Zhu F, Shao X. Status epilepticus-related etiology, incidence and mortality: a meta-analysis. Epilepsy Res. 2017;136:12–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Marawar R, Basha M, Mahulikar A, Desai A, Suchdev K, Shah A. Updates in refractory status epilepticus. Crit Care Res Pract. 2018;2018:9768949.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Alroughani R, Javidan M, Qasem A, Alotaibi N. Non-convulsive status epilepticus; the rate of occurrence in a general hospital. Seizure. 2009;18(1):38–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Veran O, Kahane P, Thomas P, Hamelin S, Sabourdy C, Vercueil L. De novo epileptic confusion in the elderly: a 1-year prospective study. Epilepsia. 2010;51(6):1030–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Gungor Tuncer O, Altindag E, Ozel Yildiz S, Nalbantoglu M, Acik ME, Tavukcu Ozkan S, et al. Reevaluation of the critically ill patients with nonconvulsive status epilepticus by using Salzburg consensus criteria. Clin EEG Neurosci. 2018;49(6):425–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Rossetti AO, Logroscino G, Liaudet L, Ruffieux C, Ribordy V, Schaller MD, et al. Status epilepticus: an independent outcome predictor after cerebral anoxia. Neurology. 2007;69(3):255–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Rossetti AO, Milligan TA, Vulliémoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011;14(1):4–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Kantanen A, Reinikainen M, Parviainen I, Kälviäinen R. Long-term outcome of refractory status epilepticus in adults: a retrospective population-based study. Epilepsy Res. 2017;133:13–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Hocker SE, Britton JW, Mandrekar JN, Wijdicks EFM, Rabinstein AA. Predictors of outcome in refractory status epilepticus. JAMA Neurol. 2013;70(1):72–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Hocker SE. Status epilepticus. CONTINUUM Lifelong Learn Neurol. 2015;21(5):1362.CrossRefGoogle Scholar
  22. 22.
    Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983;249(11):1452–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345(9):631–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Welch RD, Nicholas K, Durkalski-Mauldin VL, Lowenstein DH, Conwit R, Mahajan PV, et al. Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia. 2015;56(2):254–62.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Appleton R, Sweeney A, Choonara I, Robson J, Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol. 1995;37(8):682–8.PubMedCrossRefGoogle Scholar
  27. 27.
    DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46(4):1029–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16(6):527–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology. 2006;67(2):340–2.PubMedCrossRefGoogle Scholar
  30. 30.
    Chakravarthi S, Goyal MK, Modi M, Bhalla A, Singh P. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci. 2015;22(6):959–63.PubMedCrossRefGoogle Scholar
  31. 31.
    Navarro V, Dagron C, Elie C, Lamhaut L, Demeret S, Urien S, et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2016;15(1):47–55.PubMedCrossRefGoogle Scholar
  32. 32.
    Rossetti AO. Which anesthetic should be used in the treatment of refractory status epilepticus? Epilepsia. 2007;48(Suppl 8):52–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10(10):922–30.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia. 2001;42(3):380–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43(2):146–53.PubMedCrossRefGoogle Scholar
  36. 36.
    Krishnamurthy KB, Drislane FW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia. 1999;40(6):759–62.PubMedCrossRefGoogle Scholar
  37. 37.
    Lee WK, Liu KT, Young BWY. Very-high-dose phenobarbital for childhood refractory status epilepticus. Pediatr Neurol. 2006;34(1):63–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Fountain NB. Status epilepticus: risk factors and complications. Epilepsia. 2000;41(Suppl 2):23.CrossRefGoogle Scholar
  39. 39.
    Hyzy RC. Evidence-based critical care: a case study approach. Cham: Springer; 2017.CrossRefGoogle Scholar
  40. 40.
    Legriel S, Lemiale V, Schenck M, Chelly J, Laurent V, Daviaud F, et al. Hypothermia for neuroprotection in convulsive status epilepticus. N Engl J Med. 2016;375(25):2457–67.PubMedCrossRefGoogle Scholar
  41. 41.
    Höfler J, Trinka E. Intravenous ketamine in status epilepticus. Epilepsia. 2018;59:198–206.PubMedCrossRefGoogle Scholar
  42. 42.
    Seder DB, Sunde K, Rubertsson S, Mooney M, Stammet P, Riker RR, et al. Neurologic outcomes and postresuscitation care of patients with myoclonus following cardiac arrest. Crit Care Med. 2015;43(5):965–72.PubMedCrossRefGoogle Scholar
  43. 43.
    Mikhaeil-Demo Y, Gavvala JR, Bellinski II, Macken MP, Narechania A, Templer JW, et al. Clinical classification of post anoxic myoclonic status. Resuscitation. 2017;119:76–80.PubMedCrossRefGoogle Scholar
  44. 44.
    Stecker MM, Cheung AT, Pochettino A, Kent GP, Patterson T, Weiss SJ, et al. Deep hypothermic circulatory arrest: I. Effects of cooling on electroencephalogram and evoked potentials. Ann Thorac Surg. 2001;71(1):14–21.PubMedCrossRefGoogle Scholar
  45. 45.
    Rossetti AO, Oddo M, Liaudet L, Kaplan PW. Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology. 2009;72(8):744–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Rajiv KR, Radhakrishnan A. Status epilepticus in pregnancy: etiology, management, and clinical outcomes. Epilepsy Behav. 2017;11(76):114–9.CrossRefGoogle Scholar
  47. 47.
    Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Hauser WA, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):126–32.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Harutyunyan G, Hauer L, Dünser MW, Karamyan A, Moser T, Pikija S, et al. Autoimmune encephalitis at the neurological intensive care unit: etiologies, reasons for admission and survival. Neurocrit Care. 2017;27(1):82–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Holzer FJ, Seeck M, Korff CM. Autoimmunity and inflammation in status epilepticus: from concepts to therapies. Expert Rev Neurother. 2014;14(10):1181–202.PubMedCrossRefGoogle Scholar
  50. 50.
    Spatola M, Novy J, Du Pasquier R, Dalmau J, Rossetti AO. Status epilepticus of inflammatory etiology: a cohort study. Neurology. 2015;85(5):464–70.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Kirmani BF, Barr D, Robinson DM, Pranske Z, Fonkem E, Benge J, et al. Management of autoimmune status epilepticus. Front Neurol. 2018;9:259.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Zeiler FA, Matuszczak M, Teitelbaum J, Kazina CJ, Gillman LM. Plasmapheresis for refractory status epilepticus, Part I: A scoping systematic review of the adult literature. Seizure. 2016;43:14–22.PubMedCrossRefGoogle Scholar
  53. 53.
    Toledano M, Britton JW, McKeon A, Shin C, Lennon VA, Quek AML, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014;82(18):1578–86.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Neurological SciencesRush University Medical CenterChicagoUSA
  2. 2.Department of Neurological Sciences, Neurocritical CareRush University Medical CenterChicagoUSA

Personalised recommendations